Cohort demographics, transplantation, and novel therapy use
| Characteristic . | Full cohort, % (n) . | AAs, % (n) . | Whites, % (n) . | P . |
|---|---|---|---|---|
| Age at diagnosis, y | <.001 | |||
| Median | 69.5 | 65.6 | 70.1 | |
| IQR | 62.6-77.0 | 58.6-73.6 | 63.5-77.5 | |
| Sex | <.001 | |||
| Female | 2.2 (262) | 3.4 (110) | 1.7 (152) | |
| Male | 97.8 (11 837) | 96.6 (3144) | 98.3 (8693) | |
| Rural | 33.6 (4026) | 17.1 (554) | 39.7 (3472) | <.001 |
| Income, $ | <.001 | |||
| Mean | 45 800 | 29 700 | 51 900 | |
| SD | 74 300 | 31 300 | 84 200 | |
| ISS stage | .942 | |||
| I | 24.2 (761) | 24.2 (230) | 24.2 (531) | |
| II | 35.9 (1132) | 36.3 (346) | 35.8 (786) | |
| III | 39.9 (1257) | 39.5 (376) | 40.1 (881) | |
| Transplantation | 9.4 (1136) | 10.1 (330) | 9.1 (806) | .092 |
| Novel therapy at induction | 81.8 (9898) | 82.5 (2686) | 81.5 (7212) | .213 |
| Thalidomide | 23.1 (2791) | 19.8 (645) | 24.3 (2146) | <.001 |
| Lenalidomide | 38.8 (4692) | 37.4 (1216) | 39.3 (3476) | .056 |
| Bortezomib | 31.3 (3786) | 40.4 (1314) | 27.9 (2472) | <.001 |
| Thalidomide and bortezomib | 1.7 (205) | 2.4 (78) | 1.4 (127) | <.001 |
| Lenalidomide and bortezomib | 9.9 (1195) | 12.7 (414) | 8.8 (781) | <.001 |
| Novel therapy over lifetime | 90.3 (10 929) | 90.8 (2955) | 90.2 (7974) | .293 |
| Thalidomide | 31.0 (3752) | 28.0 (912) | 32.1 (2840) | <.001 |
| Lenalidomide | 60.0 (7254) | 60.0 (1953) | 59.9 (5301) | .948 |
| Bortezomib | 46.6 (5634) | 57.9 (1885) | 42.4 (3749) | <.001 |
| Thalidomide and bortezomib | 11.7 (1418) | 13.8 (449) | 11.0 (969) | <.001 |
| Lenalidomide and bortezomib | 30.9 (3744) | 38.5 (1253) | 28.2 (2491) | <.001 |
| Characteristic . | Full cohort, % (n) . | AAs, % (n) . | Whites, % (n) . | P . |
|---|---|---|---|---|
| Age at diagnosis, y | <.001 | |||
| Median | 69.5 | 65.6 | 70.1 | |
| IQR | 62.6-77.0 | 58.6-73.6 | 63.5-77.5 | |
| Sex | <.001 | |||
| Female | 2.2 (262) | 3.4 (110) | 1.7 (152) | |
| Male | 97.8 (11 837) | 96.6 (3144) | 98.3 (8693) | |
| Rural | 33.6 (4026) | 17.1 (554) | 39.7 (3472) | <.001 |
| Income, $ | <.001 | |||
| Mean | 45 800 | 29 700 | 51 900 | |
| SD | 74 300 | 31 300 | 84 200 | |
| ISS stage | .942 | |||
| I | 24.2 (761) | 24.2 (230) | 24.2 (531) | |
| II | 35.9 (1132) | 36.3 (346) | 35.8 (786) | |
| III | 39.9 (1257) | 39.5 (376) | 40.1 (881) | |
| Transplantation | 9.4 (1136) | 10.1 (330) | 9.1 (806) | .092 |
| Novel therapy at induction | 81.8 (9898) | 82.5 (2686) | 81.5 (7212) | .213 |
| Thalidomide | 23.1 (2791) | 19.8 (645) | 24.3 (2146) | <.001 |
| Lenalidomide | 38.8 (4692) | 37.4 (1216) | 39.3 (3476) | .056 |
| Bortezomib | 31.3 (3786) | 40.4 (1314) | 27.9 (2472) | <.001 |
| Thalidomide and bortezomib | 1.7 (205) | 2.4 (78) | 1.4 (127) | <.001 |
| Lenalidomide and bortezomib | 9.9 (1195) | 12.7 (414) | 8.8 (781) | <.001 |
| Novel therapy over lifetime | 90.3 (10 929) | 90.8 (2955) | 90.2 (7974) | .293 |
| Thalidomide | 31.0 (3752) | 28.0 (912) | 32.1 (2840) | <.001 |
| Lenalidomide | 60.0 (7254) | 60.0 (1953) | 59.9 (5301) | .948 |
| Bortezomib | 46.6 (5634) | 57.9 (1885) | 42.4 (3749) | <.001 |
| Thalidomide and bortezomib | 11.7 (1418) | 13.8 (449) | 11.0 (969) | <.001 |
| Lenalidomide and bortezomib | 30.9 (3744) | 38.5 (1253) | 28.2 (2491) | <.001 |
Reported are characteristics for AAs, whites, and the full cohort (AAs and whites together), as well as P values relative to the difference between races. Novel therapy includes thalidomide, lenalidomide, pomalidomide, bortezomib, carfilzomib, and ixazomib.
IQR, interquartile range; ISS, International Staging System; SD, standard deviation.